comprehensive -WSS

comprehensive

author：knowledge 2025-10-01 12:35:50 - browse：4653

Balance innovation — Medicare laid out in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be. Adobe

WASHINGTON — Medicare laid out Wednesday in the greatest detail yet how it will choose which drug prices it will negotiate in its brand-new program, and how it will figure out what the government’s opening offer will be.

Democrats outlined some parts of the process in the Inflation Reduction Act that passed Congress last August, but the details of how drugs will be selected and what factors will be considered have been vague until now. Though the actual negotiated prices won’t take effect for years, Medicare officials must announce the first 10 drugs they’ll negotiate over by Sept. 1.

The guidance clarifies that the agency will choose the 50 pharmacy drugs that cost Medicare the most money, based on gross expenditures. If drugs have the same cost to the program, then the one that has been approved longer will be ranked higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： State Dept. review finds Biden bears some blame for Afghanistan failures

WSS

What do new weight loss drugs mean for bariatric surgery?

United colonoscopy coverage change 'may cost lives,' doctors say

Diversity in medical illustrations gets boost from Chidiebere Ibe

Why more medical students aren't specializing in primary care

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study finds new variant for Parkinson’s in African populations

entertainment

comprehensive

leisure time

Medicare details structure of new drug price negotiation program

Heart attack and stroke risk calculators need revising

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Trump demands the U.S. pay no more for drugs than other countries … again

BioMarin wins approval for gene therapy to treat hemophilia A

The high cost of giving birth even with insurance

Drug repurposing or repositioning? The language matters

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

At least 13 dead in Texas as scorching temps continue

Neuroscience startup Neumora files for IPO

entertainment

Dobbs anniversary: the lost opportunity of abortion as health care

Continuity nursing helped my family in our darkest PICU moments

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

In science, is the line between industry and academia shifting?

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

What AAP's gender

hotspot

focus

entertainment

leisure time